(NASDAQ: AVDL) Avadel Pharmaceuticals's forecast annual revenue growth rate of 27.56% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Avadel Pharmaceuticals's revenue in 2025 is $194,450,000.On average, 4 Wall Street analysts forecast AVDL's revenue for 2025 to be $25,227,095,775, with the lowest AVDL revenue forecast at $25,152,123,100, and the highest AVDL revenue forecast at $25,297,231,503. On average, 4 Wall Street analysts forecast AVDL's revenue for 2026 to be $32,715,656,733, with the lowest AVDL revenue forecast at $31,376,596,395, and the highest AVDL revenue forecast at $34,148,844,055.
In 2027, AVDL is forecast to generate $38,806,823,775 in revenue, with the lowest revenue forecast at $35,542,174,936 and the highest revenue forecast at $40,823,830,570.